Ultragenyx to sell priority review voucher for $203 million
Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $203M. The voucher was received after FDA approval of FAYUVI, a treatment for Sanfilippo syndrome Type A. This is Ultragenyx's second such sale in a week. The deal is subject to regulatory approval. Jefferies LLC and Gibson Dunn are advisors.
How this was made
The 30-second read
Why it matters
The transaction provides non‑dilutive funding, potentially supporting further R&D and improving cash flow.
Market read
A sizable voucher sale can positively affect Ultragenyx's stock and signal value in the PRV market.
What to watch
Future regulatory scrutiny of PRV sales could affect long‑term valuation.
Background
Ultragenyx received the voucher after FDA approval of its Sanfilippo syndrome therapy and is now monetizing it.
Ticker impact
Ultragenyx Pharmaceutical announced the sale of a Rare Pediatric Disease Priority Review Voucher for $203 million.
likely upward pressure as the market prices in the non‑dilutive funding.
A $203M voucher sale is a material, one‑time cash event that strengthens financial position, typically viewed favorably by investors.
Market effects
Highlights continued demand for rare‑disease drug development incentives.
May boost sentiment for US biotech firms leveraging PRV programs.
Shows the value of FDA priority review vouchers in financing rare disease pipelines.
Counterpoint
The cash may be a one‑off and not indicative of sustainable earnings growth.
Key entities
- companyUltragenyx Pharmaceutical Inc.
US biotech firm developing rare disease therapies.
- advisorJefferies LLC
Exclusive financial advisor for the voucher sale.
